Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro …

YK Kang, LT Chen, MH Ryu, DY Oh, SC Oh… - The Lancet …, 2022 - thelancet.com
Background The additive or synergistic sustained antitumour effect of immune checkpoint
inhibitors in combination with oxaliplatin-based chemotherapy has previously been …
被引用次数：375 相关文章

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro …

YK Kang, LT Chen, MH Ryu, SC Oh… - The Lancet …, 2022 - snucm.elsevierpure.com
Background: The additive or synergistic sustained antitumour effect of immune checkpoint
inhibitors in combination with oxaliplatin-based chemotherapy has previously been …

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro …

YK Kang, LT Chen, MH Ryu, DY Oh, SC Oh, HC Chung… - 2022 - ir.nhri.org.tw
Background: The additive or synergistic sustained antitumour effect of immune checkpoint
inhibitors in combination with oxaliplatin-based chemotherapy has previously been …

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro …

YK Kang, LT Chen, MH Ryu, DYOSC Oh, HC Chung… - 2022 - ir.ymlib.yonsei.ac.kr
Background: The additive or synergistic sustained antitumour effect of immune checkpoint
inhibitors in combination with oxaliplatin-based chemotherapy has previously been …

[引用][C] Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or …

YK Kang, LT Chen, MH Ryu, DY Oh, SC Oh… - The Lancet …, 2022 - cir.nii.ac.jp
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative,
untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer …

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro …

YK Kang, LT Chen, MH Ryu, DY Oh, SC Oh… - The Lancet …, 2022 - europepmc.org
Background The additive or synergistic sustained antitumour effect of immune checkpoint
inhibitors in combination with oxaliplatin-based chemotherapy has previously been …

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro …

YK Kang, LT Chen, MH Ryu, DY Oh, SC Oh, HC Chung… - 2022 - ir.nhri.edu.tw
Background: The additive or synergistic sustained antitumour effect of immune checkpoint
inhibitors in combination with oxaliplatin-based chemotherapy has previously been …

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro …

YK Kang, LT Chen, MH Ryu, DY Oh, SC Oh, HC Chung… - 2022 - 211.76.174.198
Background: The additive or synergistic sustained antitumour effect of immune checkpoint
inhibitors in combination with oxaliplatin-based chemotherapy has previously been …

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro …

YK Kang, LT Chen, MH Ryu, DY Oh, SC Oh, HC Chung… - 2022 - scholarworks.bwise.kr
Background: The additive or synergistic sustained antitumour effect of immune checkpoint
inhibitors in combination with oxaliplatin-based chemotherapy has previously been …

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro …

YK Kang, LT Chen, MH Ryu, SC Oh… - The Lancet …, 2022 - yonsei.elsevierpure.com
Background: The additive or synergistic sustained antitumour effect of immune checkpoint
inhibitors in combination with oxaliplatin-based chemotherapy has previously been …